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Observational studies have shown that the presence of diabetes and hypertension are associated with an increased risk of mortality from COVID‐19, but whether the increased risk of death occurred independent of concurrent drugs that patients are taking is unclear. Relevant to this is the speculation that ACE and ARB -- drugs widely used in people with diabetes and hypertension ‐ maybe deleterious to COVID‐19 outcome due to the propensity of the virus to bind to cellular ACE‐2 receptors. In the absence of clear evidence, guideline from national and international hypertension societies have recommended that patients should not discontinue these drugs in the event of COVID‐19 infection. A recent study from the USA, published in the New England Journal of Medicine, have provided some reassurance of the safety of these classes of drugs during COVID‐19 infection. The study investigated clinical outcomes of 8910 patients admitted to hospital with COVID‐19. After adjusting for confounders, they identified that age above 65 years old, having cardiovascular disease, COPD and being a current smoker was associated with a significant doubling of mortality rate. However, reassuringly, the use of ACE and ARB was not associated with an increased risk of mortality. *NEJM* (doi:10.1056/NEJMoa2007621).
